Abstract 345P
Background
Breast cancer surgery can impair shoulder function, and the effects of rehabilitation exercise during early recovery remain uncertain. This study aims to assess the effectiveness of tailored exercise intervention on shoulder function recovery at one and six months post-surgery.
Methods
A total of 122 breast cancer patients (Stage 0-3) scheduled for surgery were evaluated, and 58 patients (mean age 50.2±6.6 years) were randomly assigned to an exercise or usual care group (1:1). The exercise group underwent five tailored exercise education sessions, starting one day before hospital discharge and continuing for four weeks after surgery. Participants received exercise diaries, online links, and QR codes for home-based workouts. The primary outcome measured the proportion of participants achieving 90% of their pre-surgery shoulder ROM and strength at one and six months post-surgery. Secondary measures included DASH and SPADI scores, physical activity levels, and body composition.
Results
Out of 58 participants, 56 (96.6%) completed the trial, with a 96.6% exercise compliance rate one month after surgery. In the exercise group, 92.9% and 96.2% achieved pre-surgery shoulder strength levels at one and six months post-surgery, respectively, compared to 3.7% and 32.1% in the control group. The exercise group also exhibited significantly lower shoulder pain and disability scores (SPADI) at one and six months after surgery, as well as higher physical activity levels at six months. Table: 345P
Change in shoulder strength among postoperative breast cancer patients
Affected arm | |||
EPET (n=25) | Usual Care (n=26) | p | |
Sum of strength (Ib) | |||
T0 | 44.1±10.2 | 47.5±11.1 | 0.36 |
T1 | 23.2±10.3∗∗∗ | 23.8±9.4∗∗∗ | 0.80 |
T2 | 40.4±11.9 | 28.5±11.9∗∗∗ | 0.001 |
T3 | 45.9±14.7 | 32.0±11.2∗∗∗ | <0.001 |
T4 | 51.3±14.0 | 32.0±9.2∗∗∗ | <0.001 |
T5 | 61.0±17.1∗∗∗ | 38.3±8.4∗∗∗ | <0.001 |
Mean±SD, P=represented the results of independent T-test (the p-value adjusted for Bonferroni method (0.05/6=0.0083), *=represented paired t-test [**p<0.01 vs. baseline, ***p<0.001 vs. baseline (p-value adjusted for Bonferroni method)] Abbreviation: early postoperative exercise therapy; EPET
.Conclusions
Early implementation of tailored exercise during rehabilitation significantly improved shoulder function beyond pre-surgery levels. This study provides essential insights into the efficacy and safety of early rehabilitation exercises for breast cancer patients during the post-surgery recovery phase.
Clinical trial identification
The Institutional Ethics Review Board of Severance Hospital and WHO International Clinical Trials Registry Platform (ICTRP; KCT0006997) approved the trial.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This research was supported by the Ministry of Education of the Republic of Korea, the National Research Foundation of Korea (NRF-2020S1A5B5A17090332) and Korea Breast Cancer Foundation (KBCF-2020U002).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
413P - Characteristics of patients (pts) with previously treated, oestrogen receptor-positive, HER2-negative advanced breast cancer (ER+, HER2– aBC) who had rapid progression (RP) in acelERA BC
Presenter: Miguel Martin Jimenez
Session: Poster session 03
414P - Trastuzumab deruxtecan for HER2-positive breast cancer brain metastasis: A systematic review and meta-analysis
Presenter: Isabella Michelon
Session: Poster session 03
415P - Patterns of time-to-progression intervals across clinical and liquid biopsy (LB) features in hormone receptor-positive (HR+) HER2-negative (HER2-) metastatic breast cancer (MBC) patients (pts) treated with first-line endocrine therapy (ET)
Presenter: Linda Cucciniello
Session: Poster session 03
416P - Cost-effectiveness of first-line (1L) ribociclib use vs palbociclib in the treatment of postmenopausal women with HR+/HER2− advanced breast cancer (ABC): Analysis based on final overall survival (OS) results of MONALEESA-2 (ML-2) and PALOMA-2 (PAL-2)
Presenter: Sandeep Sehdev
Session: Poster session 03
417P - New insights into second-line (2L) choices after CDK4/6 inhibitors (CDK4/6i) in hormone receptor-positive (HR+)/ human epidermal growth factor 2-negative (HER2-) metastatic breast cancer (MBC) patients (pts): Preliminary results of the HERMIONE-13 study
Presenter: Viola Cogliati
Session: Poster session 03
418P - Two-year follow-up data on the efficacy and safety of KN026, a HER2-targeted bispecific antibody combined with docetaxel as first-line treatment for HER2-positive recurrent/metastatic breast cancer
Presenter: Qingyuan Zhang
Session: Poster session 03
419P - Aspire to ASCENT: Real-world outcomes from patients with metastatic triple-negative breast cancer (mTNBC) treated with Sacituzumab govitecan (Saci) in a single academic institution
Presenter: Elaine Walsh
Session: Poster session 03
421P - Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancer
Presenter: Takayuki Iwamoto
Session: Poster session 03
422P - UK real-world data (RWD) of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) use in metastatic breast cancer (MBC)
Presenter: Georgina Gullick
Session: Poster session 03
423P - A real-world study on the clinical value of apatinib-based regimens in metastatic triple-negative breast cancer
Presenter: Huang wei
Session: Poster session 03